Ionis (NASDAQ: IONS) executive reverses previously reported sale and option exercise

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive files corrective Form 4/A. EVP and Chief Scientific Officer C. Frank Bennett reports that an earlier filing on February 4, 2026 mistakenly showed a sale of 20,000 common shares and the exercise of 65,089 stock options. These transactions were executed in error and fully reversed on February 12, 2026.

Following the reversal, Bennett is shown as directly beneficially owning 100,293 shares of Ionis Pharmaceuticals common stock as of February 12, 2026. The current filing uses a corrective "J" transaction code with zero shares at a price of $0.0 to document the adjustment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BENNETT C FRANK

Role EVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Other	Common Stock	0	$0.00	--

Holdings After Transaction: Common Stock — 100,293 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENNETT C FRANK

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		J		0(1)	D	$0.0	100,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 4, 2026, the reporting person filed a Form 4 reporting the sale of 20,000 shares of common stock and the exercise of 65,089 stock options, which transactions were executed in error and subsequently reversed on February 12, 2026. Shares beneficially owned by the reporting person as of February 12, 2026 is 100,293.

	By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Ionis Pharmaceuticals (IONS) Form 4/A filing report?

The Form 4/A reports a correction to an earlier insider filing. A previously reported stock sale and stock option exercise by executive C. Frank Bennett were executed in error and later fully reversed, with updated share ownership disclosed as of February 12, 2026.

Which insider is involved in the latest Ionis Pharmaceuticals (IONS) Form 4/A?

The filing involves C. Frank Bennett, EVP and Chief Scientific Officer. He is the reporting person correcting prior transaction data, with his direct beneficial ownership restated to 100,293 common shares as of February 12, 2026 after erroneous trades were reversed.

What transactions were corrected in the Ionis Pharmaceuticals (IONS) Form 4/A?

The correction covers an earlier reported sale of 20,000 common shares and the exercise of 65,089 stock options. These transactions, originally filed on February 4, 2026, were executed in error and subsequently reversed on February 12, 2026, prompting this amended report.

How many Ionis Pharmaceuticals (IONS) shares does the insider own after the correction?

After reversing the erroneous transactions, C. Frank Bennett beneficially owns 100,293 shares of Ionis common stock. The filing states this ownership level is as of February 12, 2026, reflecting his direct holdings following the cancellation of the mistaken transactions.

What does transaction code "J" indicate in the Ionis Pharmaceuticals (IONS) Form 4/A?

The filing uses transaction code "J" with zero shares and a price of $0.0. In this context, it documents an adjustment to previously reported activity, clarifying that the earlier sale and option exercise were erroneous and have been fully reversed without an ongoing transaction.

Is the Ionis Pharmaceuticals (IONS) Form 4/A reporting new insider buying or selling?

The Form 4/A does not report new buying or selling. Instead, it corrects an earlier filing that mistakenly showed a stock sale and option exercise. Those transactions were executed in error, then reversed on February 12, 2026, leaving updated ownership unchanged by new trades.